RA'ANANA, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has successfully achieved all key strategic objectives in its high-level talks with a government health authority, located outside of the United States, on July 8, 2025, a meeting previously announced by the Company on July 7, 2025, establishing a definitive pa ...

Core Insights - Inspira Technologies is engaged in high-level discussions with a government health authority outside the U.S. to integrate its FDA-cleared ART100 system into national emergency infrastructure and establish a global distribution framework [1][2][5] - The meeting scheduled for July 8, 2025, aims to define key terms and a roadmap for this strategic collaboration, initiated by the government seeking next-generation medical technologies [2][3] - The government involved has extensive commercial ties and diplomatic channels, which will be leveraged to enhance the profitability of a recent $22.5 million purchase order received by Inspira [3][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with its ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [6] - The company is also developing the INSPIRA ART500, a next-generation system for oxygenation while patients remain awake, and advancing the HYLA blood sensor platform for continuous, non-invasive monitoring [6] - Recent internal shifts within the company may align with broader industry trends such as consolidation, cross-sector collaboration, and potential strategic partnerships [6]

RA'ANANA, Israel, July 02, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its FDA-cleared ART100 system, representing a major commercial inflection point for the Company. The order was placed by a privately held company headquartered outside the United States, in a global strategic hub ...

RA'ANANA, Israel, June 05, 2025 (GLOBE NEWSWIRE) -- RA'ANANA, Israel, June 5, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced preparations for scaled-up its production capabilities for its U.S. Food and Drug Administration (FDA)-cleared INSPIRA™ ART100 system (the “ART100 system”), in response to expected demand from a European governmental authority with whic ...

Following successful clinical implementations in the U.S., Inspira accelerates commercialization of its system. The Company is already engaged in discussions with governmental health departments and private organizationsRA'ANANA, Israel, May 29, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira" or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced a strategic shift to accelerate the commercialization of its U.S. FDA (Food ...